Home → Schizophrenia Treatment

Schizophrenia and Psychotic Disorders: A Comprehensive Psychiatrist's Guide

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Board-Certified in Adult Psychiatry and Child & Adolescent Psychiatry
March 29, 2026

Understanding Schizophrenia: What It Is (and What It Is Not)

Schizophrenia is a chronic neuropsychiatric disorder characterized by disruptions in thinking, perception, emotions, and behavior. It affects approximately 1% of the global population and typically emerges in late adolescence or early adulthood (ages 16-30), though it can develop at any age.

What schizophrenia is NOT:

• It is NOT "split personality" (that is dissociative identity disorder, a completely different condition)
• It is NOT a result of bad parenting, moral failure, or weakness
• It does NOT mean someone is violent (despite media portrayals, people with schizophrenia are more likely to be victims of violence than perpetrators)
• It is NOT a hopeless condition (many people with schizophrenia live full, meaningful lives with proper treatment)

Positive Symptoms

"Positive" symptoms refer to experiences that are added to normal experience -- things that are present but should not be.

Hallucinations: Sensory experiences without an external source. Auditory hallucinations (hearing voices) are the most common, affecting approximately 70-80% of individuals with schizophrenia. The voices may be commanding, commenting, or conversational. Visual hallucinations occur in some cases. Tactile, olfactory, and gustatory hallucinations are less common but can occur.

Delusions: Fixed false beliefs that persist despite contradictory evidence. Common types include persecutory delusions (believing others are plotting against you), referential delusions (believing neutral events or comments are directed at you), grandiose delusions (believing you have special powers, are famous, or have a special relationship with a deity), and bizarre delusions (beliefs that are clearly implausible, such as alien implants or mind control).

Disorganized thinking/speech: Loosening of associations (jumping between unrelated topics), tangentiality (going off on tangents without returning to the original point), word salad (incomprehensible speech), and neologisms (made-up words).

Grossly disorganized or catatonic behavior: Unpredictable agitation, bizarre posturing, waxy flexibility (maintaining positions placed in by others), or complete immobility (catatonia).

Negative Symptoms

"Negative" symptoms refer to things that are diminished or absent from normal experience. They are often more disabling than positive symptoms and less responsive to medication.

• Flat affect (affective flattening): Reduced emotional expression in face, voice, and gestures
• Alogia: Poverty of speech -- reduced quantity and content of speech
• Avolition: Decrease in motivated, self-initiated purposeful activity (difficulty starting and completing tasks)
• Anhedonia: Reduced ability to experience pleasure from activities previously enjoyed
• Asociality: Reduced desire for social interaction

Negative symptoms are often mistaken for depression or laziness, which adds stigma to an already stigmatized condition. Understanding that these are neurobiological symptoms of the illness -- not character flaws -- is essential for patients, families, and treatment teams.

Cognitive Symptoms

Cognitive deficits in schizophrenia affect working memory, attention and concentration, processing speed, executive function (planning, organization, abstract thinking), and verbal learning and memory. These cognitive deficits are present even before the first psychotic episode (in the prodromal phase) and persist even when positive symptoms are well-controlled. They are often the strongest predictor of functional outcomes -- meaning a patient's ability to work, live independently, and maintain relationships depends more on their cognitive function than on whether they hear voices.

First-Episode Psychosis: Why Early Intervention Is Critical

First-episode psychosis (FEP) is one of the most important windows of opportunity in all of psychiatry. The duration of untreated psychosis (DUP) -- the time from onset of psychotic symptoms to initiation of adequate treatment -- is one of the strongest predictors of long-term outcome.

What the research shows:

• Shorter DUP is associated with better treatment response, greater likelihood of remission, preserved cognitive function, better social and occupational outcomes, and reduced risk of treatment resistance
• Longer DUP is associated with poorer response to antipsychotic medication, greater negative symptom burden, more cognitive decline, and poorer overall prognosis
• The RAISE (Recovery After an Initial Schizophrenia Episode) study demonstrated that coordinated specialty care for FEP -- combining low-dose antipsychotic medication, individual therapy (CBT), family education and support, and supported employment and education -- produced significantly better outcomes than treatment as usual

The average DUP in the United States is approximately 74 weeks -- nearly a year and a half of untreated psychosis. This is unacceptable and represents a failure of our mental health system to identify and treat psychosis early. Every week of untreated psychosis matters.

Warning signs that should prompt urgent evaluation:

• Social withdrawal and isolation that is new or worsening
• Decline in school or work performance
• Unusual or bizarre beliefs or fears
• Suspiciousness or paranoia
• Hearing or seeing things others do not
• Decline in personal hygiene
• Flat or inappropriate emotional responses
• Confused or disorganized speech
• Sleep disturbance with increasing agitation

Antipsychotic Medications: First-Generation vs. Second-Generation

First-Generation (Typical) Antipsychotics

Developed in the 1950s, first-generation antipsychotics (FGAs) revolutionized the treatment of schizophrenia by blocking dopamine D2 receptors. They are effective for positive symptoms but carry significant neurological side effects.

Key FGAs:

• Haloperidol (Haldol): High-potency, effective for acute psychosis and agitation. Available in long-acting injectable (decanoate) form. Higher risk of EPS.
• Chlorpromazine (Thorazine): Low-potency, more sedating, lower EPS risk but more anticholinergic and metabolic effects.
• Fluphenazine: Available as long-acting injectable (decanoate). Commonly used for maintenance treatment.

Side effects of FGAs: Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism), tardive dyskinesia (involuntary movements, particularly facial, with long-term use; potentially irreversible), neuroleptic malignant syndrome (rare but life-threatening: fever, rigidity, autonomic instability), and prolactin elevation (causing breast enlargement, lactation, menstrual irregularities, sexual dysfunction).

Second-Generation (Atypical) Antipsychotics

Developed starting in the 1990s, second-generation antipsychotics (SGAs) block both dopamine D2 and serotonin 5-HT2A receptors. They have lower EPS risk but introduced a new set of metabolic concerns.

Key SGAs:

• Risperidone (Risperdal): Well-studied, effective, available as long-acting injectable (Risperdal Consta). Dose-dependent EPS and prolactin elevation.
• Olanzapine (Zyprexa): Highly effective but carries the highest metabolic risk (weight gain averaging 10-15 lbs in the first year, diabetes risk, dyslipidemia). Available as long-acting injectable (Zyprexa Relhypv).
• Quetiapine (Seroquel): Sedating, useful when insomnia is prominent. Lower EPS risk. Metabolic effects moderate.
• Aripiprazole (Abilify): Partial dopamine agonist with a favorable metabolic profile (weight-neutral or minimal gain). Available as long-acting injectable (Abilify Maintena, Aristada). May cause akathisia.
• Ziprasidone (Geodon): Weight-neutral. Requires QTc monitoring (cardiac conduction). Must be taken with food for absorption.
• Lurasidone (Latuda): Favorable metabolic profile. Also effective for bipolar depression. Must be taken with food.
• Cariprazine (Vraylar): Partial dopamine agonist with emerging evidence for efficacy against negative symptoms -- a significant advantage if confirmed, as most antipsychotics do little for negative symptoms.
• Paliperidone (Invega): Active metabolite of risperidone. Available as monthly and 3-monthly long-acting injectable (Invega Sustenna, Invega Trinza). Useful for adherence challenges.

Long-Acting Injectable Antipsychotics (LAIs)

LAIs are administered by injection every 2-12 weeks rather than taken daily by mouth. They eliminate the daily adherence burden -- a critical advantage given that medication non-adherence is the single biggest risk factor for relapse in schizophrenia. Studies consistently show that LAIs reduce relapse and hospitalization rates compared to oral antipsychotics, primarily by ensuring consistent medication delivery. I recommend LAIs for any patient who has experienced relapse due to non-adherence, who prefers the convenience of less frequent dosing, or who wants to eliminate the daily reminder of their illness.

Clozapine: The Gold Standard for Treatment-Resistant Schizophrenia

Clozapine (Clozaril) stands alone in the antipsychotic armamentarium. It is the only antipsychotic proven to be effective in treatment-resistant schizophrenia -- defined as failure to respond to at least two adequate trials of other antipsychotics. Approximately 30% of patients with schizophrenia are treatment-resistant, and among these, 30-60% will respond to clozapine.

Clozapine is also the only antipsychotic proven to reduce suicide risk in schizophrenia (the InterSePT trial demonstrated a 26% reduction in suicidal behavior). Given that approximately 5% of individuals with schizophrenia die by suicide, this property is clinically significant.

Why is clozapine underused? Despite its superior efficacy and anti-suicidal properties, clozapine is significantly underutilized. In the United States, only 4-5% of eligible patients receive it, compared to much higher rates in some other countries. The primary barriers are the monitoring requirement for agranulocytosis (a dangerous drop in white blood cells that occurs in 1-2% of patients, requiring weekly blood draws for the first 6 months, then biweekly, then monthly), prescriber unfamiliarity (many psychiatrists have limited experience prescribing and managing clozapine), side effect burden (significant weight gain, sedation, drooling, constipation, metabolic effects, seizure risk at high doses), and the REMS (Risk Evaluation and Mitigation Strategy) program that requires registration of prescribers, pharmacies, and patients.

During my training, I co-authored research with Dr. Duncan at Emory University examining clozapine and FDA monitoring requirements -- specifically, how the monitoring system could be optimized to improve access without compromising safety. I believe clozapine is underused and that eligible patients should be offered this medication when other antipsychotics have failed.

Metabolic Monitoring: A Critical and Often Neglected Component

People with schizophrenia have a life expectancy 15-20 years shorter than the general population, and the leading cause of this premature mortality is cardiovascular disease -- not suicide or violence as commonly assumed. Antipsychotic medications, particularly SGAs, contribute to cardiovascular risk through metabolic side effects.

My JAMA Internal Medicine study on antipsychotic prescribing patterns highlighted that metabolic monitoring is frequently inadequate in clinical practice. Many patients on antipsychotics do not receive recommended baseline and follow-up monitoring of fasting glucose, lipids, weight, waist circumference, and blood pressure.

Recommended monitoring schedule:

I monitor these parameters systematically in all patients on antipsychotic medications and intervene early when metabolic abnormalities develop -- whether through medication switching, dose reduction, lifestyle interventions, or addition of metabolic medications (metformin, statins) when needed.

Cannabis and Psychosis: A Major Public Health Concern

The relationship between cannabis use and psychotic disorders is one of my primary areas of research. The evidence linking cannabis to psychosis is substantial and growing.

Key findings:

• Cannabis use is associated with a 2-4 fold increased risk of developing a psychotic disorder
• The risk is dose-dependent: daily use of high-potency cannabis (high THC content) carries the highest risk
• Adolescent cannabis use carries particularly high risk, as the developing brain is more vulnerable
• Cannabis can precipitate psychotic episodes in individuals with genetic vulnerability to schizophrenia
• Continued cannabis use after a first psychotic episode worsens outcomes -- more frequent relapses, longer hospitalizations, and poorer medication response
• A 2019 Lancet Psychiatry study estimated that daily use of high-potency cannabis accounts for approximately 12% of new cases of psychosis across Europe, and up to 30% in cities like Amsterdam and London where high-potency cannabis is prevalent

This is critically important in the context of cannabis legalization and increasing THC potency. The cannabis products available today are dramatically more potent than those available 20-30 years ago -- THC concentrations have increased from approximately 4% to 15-25% in flower, and concentrates can exceed 80-90% THC.

For comprehensive coverage of this topic, see my detailed guide on Cannabis and Psychosis.

The Recovery Model: Beyond Symptom Reduction

Modern schizophrenia treatment has shifted from a purely symptom-focused model to a recovery-oriented approach. Recovery does not necessarily mean cure or complete symptom remission -- it means living a meaningful, satisfying life despite the presence of illness.

Key components of recovery-oriented care:

• Medication as a foundation, not the whole treatment: Antipsychotic medication controls positive symptoms and reduces relapse risk, but medication alone is insufficient for full recovery. It must be combined with psychosocial interventions.
• Cognitive Behavioral Therapy for Psychosis (CBTp): Adapted CBT that helps patients examine and challenge delusional beliefs, develop coping strategies for hallucinations, and manage distress associated with psychotic symptoms. Evidence supports CBTp as an adjunct to medication.
• Supported employment and education: The Individual Placement and Support (IPS) model places individuals directly into competitive employment with ongoing support. IPS consistently outperforms traditional vocational rehabilitation, with employment rates of 55-65% vs. 20-25%.
• Family psychoeducation: Family-based interventions that provide education about schizophrenia, improve communication, reduce expressed emotion (hostility, criticism, overinvolvement), and teach problem-solving skills. These interventions reduce relapse rates by approximately 50% compared to medication alone.
• Peer support: Connection with individuals who have lived experience with psychotic disorders provides hope, practical strategies, and validation that recovery is possible.
• Social skills training: Structured programs that teach conversation skills, assertiveness, community living skills, and workplace behaviors.
• Cognitive remediation: Targeted interventions to improve cognitive function (attention, memory, executive function) through computer-based exercises and strategy training.

Family Education: What Families Need to Know

Schizophrenia affects not just the individual but the entire family. Families often experience grief, confusion, frustration, and burnout. Providing families with accurate information and support is an essential component of treatment.

Key messages for families:

• Schizophrenia is a brain-based illness, not a choice or a failure of parenting
• Medication adherence is critical -- stopping medication is the most common cause of relapse
• Recovery is possible but may look different from what you expect -- meaningful recovery does not require complete symptom elimination
• Stress management matters -- high levels of family conflict ("expressed emotion") increase relapse risk
• Substance use (especially cannabis) worsens outcomes and should be strongly discouraged
• Early warning signs of relapse (sleep changes, increased isolation, unusual beliefs) should prompt immediate contact with the treatment team
• Self-care for caregivers is essential -- you cannot support your family member if you are burned out
• NAMI (National Alliance on Mental Illness) offers excellent family support programs

My Approach to Psychotic Disorders

At Integrative Psych in Chelsea, Manhattan, I bring my research background at Columbia University directly to clinical practice. My JAMA study on antipsychotic prescribing ensures that I prescribe responsibly -- with clear diagnostic indications, appropriate dosing, and systematic metabolic monitoring. My cannabis research makes me particularly attuned to the role of substance use in psychotic disorders and the importance of addressing it as part of treatment.

Key elements of my approach:

• Thorough diagnostic assessment: Not all psychosis is schizophrenia. Psychotic symptoms can occur in bipolar disorder, severe depression, substance-induced psychosis, medical conditions, and brief psychotic disorder. Accurate diagnosis determines treatment.
• Evidence-based medication selection: I choose antipsychotics based on efficacy evidence, side effect profiles, patient preferences, and practical considerations (adherence history, metabolic risk, desire for LAI).
• Systematic metabolic monitoring: Following APA/ADA guidelines for weight, glucose, lipids, and cardiovascular risk assessment -- something my research showed is too often neglected.
• Clozapine advocacy: For treatment-resistant patients, I actively offer and manage clozapine rather than cycling through additional failed antipsychotic trials.
• Substance use assessment: Comprehensive evaluation of cannabis, alcohol, and other substance use, with integrated treatment when substance use disorders co-occur.
• Recovery orientation: Medication management is one component of a comprehensive treatment plan that includes therapy, family support, social skills development, and vocational/educational support.

Further Reading

• Cannabis and Psychosis: Complete Guide
• Off-Label Antipsychotic Prescribing in Children
• Psychiatric Medication Management
• Bipolar Disorder Treatment